Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment

被引:29
作者
Alessandria, C
Gaia, S
Marzano, A
Venon, WD
Fadda, M
Rizzetto, M
机构
[1] San Giovanni Battista Hosp, Dept Gastroenterol, I-10126 Turin, Italy
[2] San Giovanni Battista Hosp, Dept Clin Nutr, I-10126 Turin, Italy
关键词
portal hypertension; transjugular intrahepatic portosystemic shunt; refractory ascites; functional renal failure; model for end-stage liver disease;
D O I
10.1097/00042737-200406000-00015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Transjugular intrahepatic portosysternic shunt (TIPS) can manage severe complications of portal hypertension. The Mayo Clinic group proposed a so-called model for end-stage liver disease (MELD) to predict survival in cirrhotic patients. High creatinine levels determine a decrease in calculated survival chances with MELD but functional renal disease can be reversed by TIPS. The aim of this study was to evaluate the efficacy of MELD in predicting survival after TIPS, particularly in patients with refractory ascites associated with functional renal failure. Methods This retrospective analysis examines 68 cirrhotic patients who underwent elective TIPS: 48 patients had refractory ascites and 20 patients had recurrent variceal bleeding. Multivariate analysis was used to establish predictive parameters of survival after TIPS. Kaplan-Meier and log-rank tests were used to compare survival rates observed in our patients with those evaluated with the MELD score. Results The age of patients was the only variable shown to have an independent value in predicting survival after TIPS. In patients undergoing shunting for refractory ascites, the survival rates at 6, 12 and 24 months after the procedure were significantly higher than expected with the MELD score. Conclusions The MELD scale may underestimate the efficacy of TIPS in end-stage cirrhotic patients with refractory ascites and functional kidney dysfunction. Further studies are needed to confirm this finding and ultimately to assess a correction factor to better predict survival after TIPS in patients with functional renal impairment. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:607 / 612
页数:6
相关论文
共 31 条
[1]
Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2 [J].
Alessandria, C ;
Venon, WD ;
Marzano, A ;
Barletti, C ;
Fadda, M ;
Rizzetto, M .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (12) :1363-1368
[2]
Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt [J].
Angermayr, B ;
Cejna, M ;
Karnel, F ;
Gschwantler, M ;
Koenig, F ;
Pidlich, J ;
Mendel, H ;
Pichler, L ;
Wichlas, M ;
Kreil, A ;
Schmid, M ;
Ferlitsch, A ;
Lipinski, E ;
Brunner, H ;
Lammer, J ;
Ferenci, P ;
Gangl, A ;
Peck-Radosavljevic, M .
GUT, 2003, 52 (06) :879-885
[3]
Arroyo JLB, 2000, J PRAGMATICS, V32, P1
[4]
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[5]
Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study [J].
Brensing, KA ;
Textor, J ;
Perz, J ;
Schiedermaier, P ;
Raab, P ;
Strunk, H ;
Klehr, HU ;
Kramer, HJ ;
Spengler, U ;
Schild, H ;
Sauerbruch, T .
GUT, 2000, 47 (02) :288-295
[6]
Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation [J].
Brown, RS ;
Lombardero, M ;
Lake, JR .
TRANSPLANTATION, 1996, 62 (12) :1788-1793
[7]
Model for End-Stage Liver Disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients [J].
Brown, RS ;
Kumar, KS ;
Russo, MW ;
Kinkhabwala, M ;
Rudow, DL ;
Harren, P ;
Lobritto, S ;
Emond, JC .
LIVER TRANSPLANTATION, 2002, 8 (03) :278-284
[8]
Child-Pugh- vs. MELD-score to predict survival after TIPS: The Vienna-experience with 349 patients over 10 years [J].
Cejna, M ;
Karnel, F ;
Gschwantler, M ;
Pidlich, J ;
Kreil, A ;
Wichlas, M ;
Mendel, H ;
Pichler, L ;
Brunner, H ;
Gangl, A ;
Peck-Radosavljevic, M ;
Angermayr, B .
JOURNAL OF HEPATOLOGY, 2002, 36 :16-16
[9]
Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting [J].
Chalasani, N ;
Clark, WS ;
Martin, LG ;
Kamean, J ;
Khan, MA ;
Patel, NH ;
Boyer, TD .
GASTROENTEROLOGY, 2000, 118 (01) :138-144
[10]
Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites [J].
Deschênes, M ;
Dufresne, MP ;
Bui, B ;
Fenyves, D ;
Spahr, L ;
Roy, L ;
Lafortune, M ;
Pomier-Layrargues, G .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (05) :1361-1365